PriceTargets.com logo

Gracell Biotechnologies - GRCL Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $10.06
  • Forecasted Upside: -1.83%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$10.25 As of 02/22/2024 01:00 AM ET
+0 (0.00%)
Get New Gracell Biotechnologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GRCL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GRCL

Analyst Price Target is $10.06
▼ -1.83% Downside Potential
This price target is based on 7 analysts offering 12 month price targets for Gracell Biotechnologies in the last 3 months. The average price target is $10.06, with a high forecast of $10.25 and a low forecast of $10.00. The average price target represents a -1.83% upside from the last price of $10.25.

This chart shows the closing price for GRCL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 7 polled investment analysts is to hold stock in Gracell Biotechnologies. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
8/7/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/22/2024Stifel NicolausReiterated RatingBuy ➝ Hold$11.00 ➝ $10.25
12/27/2023Wells Fargo & CompanyReiterated RatingOverweight ➝ Equal Weight$10.00
12/27/2023Piper SandlerReiterated RatingOverweight ➝ Neutral$10.00
12/26/2023BTIG ResearchReiterated RatingBuy ➝ Neutral
12/26/2023HC WainwrightDowngradeBuy ➝ Neutral$13.00 ➝ $10.00
11/27/2023Evercore ISIInitiated CoverageOutperform
11/15/2023Cantor FitzgeraldReiterated RatingOverweight
10/19/2023Stifel NicolausInitiated CoverageBuy$11.00
9/5/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$20.00
8/30/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$20.00
8/29/2023CitigroupLower TargetBuy ➝ Buy$12.00 ➝ $11.00
8/14/2023HC WainwrightBoost TargetBuy ➝ Buy$12.00 ➝ $13.00
6/12/2023BTIG ResearchBoost Target$18.00 ➝ $20.00
3/27/2023Wells Fargo & CompanyReiterated RatingOverweight$7.00
2/16/2023HC WainwrightReiterated RatingBuy$12.00
2/6/2023HC WainwrightReiterated RatingBuy$12.00
12/8/2022HC WainwrightInitiated CoverageBuy$6.00
9/22/2022CitigroupInitiated CoverageBuy$12.00
8/18/2022Wells Fargo & CompanyReiterated RatingOverweight
6/1/2022Cantor FitzgeraldInitiated CoverageOverweight$20.00
5/27/2022Piper SandlerLower Target$25.00 ➝ $10.00
4/4/2022BTIG ResearchInitiated CoverageBuy$18.00
3/14/2022Piper SandlerLower Target$40.00 ➝ $25.00
2/3/2021CitigroupInitiated CoverageBuy$35.00
2/2/2021Jefferies Financial GroupInitiated CoverageBuy$30.00
2/2/2021Piper SandlerInitiated CoverageOverweight$40.00
2/2/2021Wells Fargo & CompanyInitiated CoverageOverweight$33.00
(Data available from 10/30/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/31/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/30/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Gracell Biotechnologies logo
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China. As of February 22, 2024, Gracell Biotechnologies Inc. operates as a subsidiary of AstraZeneca Treasury Limited.
Read More

Today's Range

Now: $10.25
Low: $10.25
High: $10.25

50 Day Range

MA: $10.25
Low: $10.14
High: $10.35

52 Week Range

Now: $10.25
Low: $1.40
High: $10.44

Volume

N/A

Average Volume

1,315,803 shs

Market Capitalization

$744.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Gracell Biotechnologies?

The following equities research analysts have issued research reports on Gracell Biotechnologies in the last year: BTIG Research, Cantor Fitzgerald, Evercore ISI, HC Wainwright, Piper Sandler, Stifel Nicolaus, and Wells Fargo & Company.
View the latest analyst ratings for GRCL.

What is the current price target for Gracell Biotechnologies?

4 Wall Street analysts have set twelve-month price targets for Gracell Biotechnologies in the last year. Their average twelve-month price target is $10.06, suggesting a possible downside of 1.8%. Stifel Nicolaus has the highest price target set, predicting GRCL will reach $10.25 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $10.00 for Gracell Biotechnologies in the next year.
View the latest price targets for GRCL.

What is the current consensus analyst rating for Gracell Biotechnologies?

Gracell Biotechnologies currently has 5 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in GRCL, but not buy more shares or sell existing shares.
View the latest ratings for GRCL.

What other companies compete with Gracell Biotechnologies?

Other companies that are similar to Gracell Biotechnologies include Allogene Therapeutics, Poseida Therapeutics, bluebird bio, Celyad Oncology and Arvinas. Learn More about companies similar to Gracell Biotechnologies.

How do I contact Gracell Biotechnologies' investor relations team?

The company's listed phone number is 86-512-6262-6701 and its investor relations email address is [email protected]. The official website for Gracell Biotechnologies is www.gracellbio.com. Learn More about contacing Gracell Biotechnologies investor relations.